ArticleVirchows Archiv : an international journal of pathology2026
Central histopathological review of a European hepatocellular carcinoma cohort: impact of the WHO 2019 classification on histological diagnosis and TNM staging.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) 2019 classification of hepatocellular carcinoma (HCC) introduces new histological subtypes aiding morphomolecular classification. We aimed to reclassify and restage archival HCC following central pathology review and evaluate the frequency of new subtypes in a large European HCC cohort. All histological material of 100 curative liver resection specimens for HCC from 100 patients (80 male, median age 72, IQR: 61.5-76.5 years, BCLC stage 0-C) operated from 2001 to 2018 was centrally reviewed. All cases were reclassified according to WHO 2019 and restaged according to TNM 2017 system. Thirty-five HCCs (35%) were classified into new subtypes: 15 macrotrabecular-massive (15%), 7 steatohepatitic (7%), 4 scirrhous (4%), 3 fibrolamellar (3%), 2 chromophobe (2%), 2 lymphocyte-rich (2%), 1 clear cell (1%), and 1 neutrophil-rich (1%). Histological grade changed in 45% HCCs (p < 0.001). TNM stage was modified from 1 to 2 in 22/100 HCCs (p < 0.001). The main histological pattern was solid (52%), pseudoglandular (17%), trabecular (16%), and macrotrabecular (15%). Microvascular invasion was detected in 64% HCCs. The non-neoplastic liver parenchyma showed steatosis (40%), steatohepatitis (19%), and/or chronic inflammation (71%). Fibrosis was staged as F0 35%, F1 17%, F2 13%, F3 11%, or F4 24%. Central histopathology review according to WHO 2019 and TNM 2017 modified histological grading in approximately half and staging in one quarter of resected HCCs, respectively, with clinical implications. One-third of HCCs were reclassified into new histological subtypes, some with known molecular background, prognostic and/or predictive impact, important for patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.